SELLAS Life Sciences SLS
NASDAQ SLS
$11.51 -0.08 (-0.69%)
At close: Sep 29, 2026 · 4:00 PM EDT

SELLAS Life Sciences (SLS) Convertible Debt (2012 - 2016)

Updated

SELLAS Life Sciences' Convertible Debt came in at $7.37 million for Q4 2016.

Analysis

SELLAS Life Sciences (SLS) Convertible Debt (2012 - 2016) Analysis & Trends

  • The Q4 2016 figure represents the lowest quarterly Convertible Debt since Q1 2012.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 655.56 Bn 574.09 Bn 17.26 Bn
2 AbbVie 470.94 Bn 444.10 Bn 12.70 Bn
3 Merck 367.14 Bn 321.57 Bn 12.21 Bn
4 Novartis Ag 280.33 Bn 236.20 Bn 11.24 Bn
5 Astrazeneca 257.78 Bn 231.34 Bn 12.86 Bn
6 Amgen 226.04 Bn 181.44 Bn 7.24 Bn
7 Gilead Sciences 188.89 Bn 163.01 Bn 6.22 Bn
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn
9 Vertex Pharmaceuticals 133.68 Bn 105.69 Bn 2.84 Bn
10 SELLAS Life Sciences 2.34 Bn 2.34 Bn -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2016 7.37 Mn
Mar 31, 2012 1.00 Mn
API Access

SELLAS Life Sciences Convertible Debt API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=convertible-debt&ticker=SLS&period=max&api_key=YOUR_API_KEY